patients with severe renal failure. The present data suggest that if stable bactericidal serum levels of cefamandole are to be maintained during hemodialysis and peritoneal dialysis, a parenteral loading dose must be administered followed by one-half the loading dose every half-life.
Cefamandole nafate is a new parenteral cephalosporin active against a wide variety of gram-positive and gram-negative organisms including cephalothin-resistant Enterobacter species, indole-positive Proteus species resistant to cephalothin, and particularly Haemophilus influenzae isolates (2, (9) (10) (11) . In previous studies, the pharmacokinetics of cefamandole have been studied in normal volunteers, but no studies have been done in patients with chronic renal failure who are not being dialyzed or in patients undergoing hemodialysis or peritoneal dialysis. Therefore, it is the purpose of this investigation to evaluate the pharmacokinetics of this agent during the course of routine hemodialysis and peritoneal dialysis and during interdialytic periods.
MATERIALS AND METHODS Patients. Eleven chronic dialysis patients with chronic renal failure (creatinine clearance <5 ml/ min) were studied. Two chronic hemodialysis patients were studied during the interdialytic period, five patients during the course of a routine hemodialysis, and four patients during the course of a routine peritoneal dialysis. No patient was septic, nor had any received antibiotics for at least 2 weeks before the study. Informed consent was obtained from each patient.
Dialysis. (i) Peritoneal. All patients studied had indwelling Tenckhoff catheters in place. Dialysis solutions (1.5% dextrose) were prewarmed to a temperature of 37°C and instilled into the peritoneal cavity over a 10-min period. Dwell time in the peritoneal cavity was limited to 20 min, and dialysate was drained over a 30-min period. Heparin was not added to the dialysate. The overall flow rate was 2 liters/h.
(ii) Hemodialysis. Patients underwent dialysis for 6 h with a recirculating single-pass delivery system using extracorporeal Ex-23 coils. An initial loading dose of heparin, 1 mg/kg ofbody weight, was given followed by hourly injections of 1,000 U of heparin through the 4th hour of dialysis.
Study protocol. Control serum samples were taken from all patients just before administration of the antibiotic as well as before institution of dialysis for those patients being studied during dialysis. (7), where ER is the extraction ratio; A is the arterial serum antibiotic concentration (in milligrams per milliliter) or arterial creatinine concentration (in milligrams per 100 ml); and V is the venous serum antibiotic concentration (micrograms per milliliter) or venous creatinine concentration (in milligrams per 100 ml). Extraction ratios for antibiotic and creatinine were then compared by the formula (A/B) x 100 = C, where A is the extraction ratio of antibiotic; B is the extraction ratio of creatinine; and C is the ratio of the percentage of antibiotic extracted to the percentage of creatinine extracted at each time interval measured.
(v) Half-life. The kinetics of the present study are characterized by a monoexponential decay curve. Thus, the half-life of the antibiotic was determined by the method of least squares using the slope (im) as calculated from the formula (6) :
NY(x log y) -(:x)(£ log y)
where x is the time in hours; y is the concentration of antibiotic in serum; and N is the number of observations.
RESULTS
Hemodialysis. In the five patients studied, the 1-h peak arterial concentration (Table 1 , Fig. 1 Fig. 2) 12.5 h after the injection (11.5 h after dialysis was begun). The mean peritoneal dialysate concentration (Table 3) was 5.79 ,ug/ml (range: 4.01 to 8.52). The mean quantity of antibiotic removed per exchange over the 12 h was 11.56 mg/h (range: 8.02 to 17.04). Total mean amount of drug removed was 139.2 mg, or 3.9% of the initial 1-g dose.
The mean clearance of cefamandole per exchange and the mean over 12 h are listed in Table 3 . The mean was 10.22 ml/min, with a range of 8.25 to 11.64. The mean half-life (Table 2) calculated by monoexponential decay was 7.15 h (range: 5.68 to 8.67).
Chronic renal patients: interdialytic period. In the two patients studied, the mean peak serum concentration was 24.63 ,ug/ml 1 h after intramuscular injection of 1 g of cefamandole. Six hours after injection, the mean serum concentration was 20.21 ,ug/ml. The half-life of cefamandole in patient 1, calculated from antibiotic concentrations at 1, 2, 3, 4, 5, and 6 h, was 8. function (creatinine, 0.8 to 1.7 mg/100 ml; creatinine clearances, 31 to 123 ml/min), Shemonsky et al. (11) observed that doses of 6 to 11 mg/kg (comparable to a dose of 500 mg) given by intramuscular injection resulted in a mean peak serum concentration of 13.7 + 3 ug/ml at 1.5 h and '1.0 ,g/ml at 6 h. In the same study, with doses in the 11-to 17-mg/kg range (approximating the 1-g intramuscular dose used in the present study), the mean peak serum concentrations were observed to be 31.0 + 17. 8 ,ug/ml at 0.5 h and 1.7 ± 0.7 u.g/ml 6 h after cefamandole administration. The calculated half-life in their study ranged from 49 to 129 min. In a similar study in normal volunteers given a 1-g intramuscular injection, the mean peak serum concentration was 21 ,ug/ml (3). In the same study (3), a 1-g intravenous dose of cefamandole given to normal volunteers resulted in a t1l2 of 0.5 h. These workers (3) observed that cefamandole was 74% bound to serum protein and had a volume of distribution of 12.8 liters/1.73 M2. The data observed in the present study, which were obtained from two patients with chronic renal failure who were studied during the interdialytic period, indicated a mean peak serum concentration of 24.63 ,ug/ml at 1 h after the injection of 1 g of cefamandole and were comparable to the results observed in normal patients (3, 11) . However, the 6-h mean serum concentration in our patients was 20.21 ug/ml, and the calculated t1/2 was 8.8 h. The striking contrast in serum levels in patients with chronic renal failure as compared with patients with normal renal function reflects the significant clearance of cefamandole by renal mechanisms.
The four patients in the present report who were studied on peritoneal dialysis again demonstrated peak serum levels comparable to those of normals, with a mean of 25.4 ug/ml.
The 12.5-h postinjection mean level of 8.71 ug/ ml suggests that cefamandole is not effectively removed by peritoneal dialysis. This statement is supported by our observations that approximately 130 mg of cefamandole, or 13% of the initial 1-g dose, was found in the dialysate over the 12-h period of dialysis. The present study also indicates that the mean half-life of cefamandole is prolonged in patients undergoing peritoneal dialysis, i.e., 7.5 h as compared with 30 min in patients with normal renal function.
Similarly, in our patients undergoing hemodialysis, the mean peak serum concentration of cefamandole was observed to be 27.85 ,ug/ ml. Thus, mean peak serum concentrations of the antibiotic, after intramuscular injection of 1 g, appear comparable regardless of renal status. In contrast to the rapid excretion of cefamandole over 6 h in patients with normal renal function, however, the patients undergoing hemodialysis had an observed mean serum concentration of 16.03 ,ug/ml at 6 h. The calculated half-life was 6.61 h, similar to the value obtained for the peritoneal dialysis study group.
The pharmacokinetics of cefamandole in renal failure and dialysis differ in certain aspects from previous data derived from cephalothin studies in patients with renal failure. Kabins and Cohen (4) studied 12 azotemic patients (creatinine clearance <5 ml/min) given 1 g of cephalothin intravenously and observed that the peak serum concentrations 15 to 30 min postinjection ranged from 32 to 64 ,ug/ml. At 6 h, serum cephalothin values in the azotemic patients were in the range of 16 ,ug/ml as compared with undetectable levels in patients with creatinine clearances greater than 30 ml/ min per 1.73 M2. The half-life of cephalothin in these azotemic patients was increased over the normal tl2 of 0.5 h and was biphasic, i.e., 2.8 h over the first 8 h and 12 ± 4 and 19 h over 8 to 24 h and 24 to 48 h, respectively, reflecting the different urine excretion rates of cephalothin and its metabolite o-desacetyl cephalothin (4). An initial half-life value for cephalothin of 2.9 h has also been reported by Kunin and Atuk in patients with renal failure (5).
Yamasaku et al. (13) also studied cephalosporins, but not cefamandole, in patients with renal failure undergoing dialysis and found that the half-life for cephalothin was prolonged in uremic patients. These workers observed cephalothin half-life values of 4.6 h over the first 9 h and 15.9 h over the subsequent 72 h. However, half-life values were. reduced to 2.3 h by hemodialysis on a coil dialyzer and to 2.6 h on the Kiil dialyzer. Cephalothin did not appear to be removed by peritoneal dialysis since the average half-life in six patients in this study was 5.1 h. Thus, both cephalothin and cefamandole have prolonged half-lives in patients with severe chronic renal insufficiency, and neither cephalothin nor cefamandole is effectively removed by peritoneal dialysis, whereas cephalothin, but not cefamandole, is significantly removed from the serum during hemodialysis.
We have no obvious explanation for the nondialyzability of cefamandole, or for the difference between the dialyzability of cefamandole and cephalothin during hemodialysis. Both cephalothin and cefamandole are similarly protein bound (70 and 74%, respectively) and have similar half-lives (30 and 34 min, respectively) as well as similar volumes of distribution (18.5 and 12.8 liters/1.73 m2, respectively) and molecular weights (418 and 512, respectively) (3) .
Even though cefamandole is not significantly removed from the serum during hemodialysis or peritoneal dialysis, our observations indicate that the concentration of cefamandole in the peritoneal dialysis fluid ranged from 8.52 ,ug/ml at 1 h to 4.02 ,ug/ml at 12 h, with a mean of 5.79 ,ug/ml. On the basis of these data, it appears that intramuscular cefamandole alone, without similar intraperitoneal instillation, should give sufficiently elevated peritoneal levels to be bactericidal for many gram-negative pathogens and, except for Streptococcus faecalis, most gram-positive organisms found in bacterial peritonitis (11) .
Since the results of the present study indicate that the clearance of cefamandole during hemodialysis and peritoneal dialysis is minimal and that the half-life is significantly prolonged (greater than six times) in patients undergoing dialysis, the following dose recommendations can be calculated according to the formula (Pk)(Vd) = dose in milligrams per square meter, where Pk is the peak serum antibiotic level felt to give adequate therapeutic levels = 25 ,tg/ml (11) and Vd is volume of distribution of the drug (12.8 liters/1.73 m2) (3) = 7.45 liters/M2. Substituting values, one gets the following: dosage (in milligrams per square meter) = (25 x 10-3 mg/ml) (7.45 x 103 ml/m2) = 186 mg/M2. Therefore, patients with severe renal failure, regardless of whether they are undergoing hemodialysis or peritoneal dialysis, should receive a loading dose of cefamandole based on the above calculation, followed by one-half this loading dose every half-life (7.5 h during peritoneal dialysis and 6.6 h during hemodialysis). This method of administration has been shown to provide more stable drug levels (1).
